SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Calamity Jane — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMartha Canary
Date of birth1856-05-01
IdentifiersMRN HR-NI008-SYN-TD; SSN (made up) 000-08-9532
Document date1901-05-11
AuthorRuth Ann Kessler, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review: recovery, mood, housing and results. [S]

History of Present Illness

Ms. Canary returns two weeks after her preventive visit, where she had her second naltrexone injection. She has had no alcohol for ten weeks. Cravings come mostly when she passes the bars in town in the evening, and she walks another way. Last week she moved into a rented room of her own through the housing program. For about two weeks in early April she had no phone after hers was lost, and she had no peer contact in that time; she now has a free phone through the Lifeline program. Her mood is steady. Her HPV test was negative and her tuberculosis blood test was negative. Her mammogram is booked at the mobile unit next month. [S]

ElementDetail
AlcoholNone for ten weeks
NaltrexoneInjections four weeks apart; next due in two weeks
HousingA rented room of her own since last week
MoodPHQ-9 5; GAD-7 5
Screening resultsHPV negative; interferon-gamma release assay negative

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight rising
GastrointestinalNegativeNo nausea or abdominal pain
IntegumentaryNegativeInjection sites healed without lumps
PsychiatricNegativeMood steady; occasional cravings; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days onlyPer the written five-day scheduleOral route1901-03-02 to 1901-03-06completedS
Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic100 mg intramuscularly once daily for three daysIntramuscular route1901-03-02 to 1901-03-04completedS
Thiamine 100 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-05activeS
Folic acid 1 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-02activeS
Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five daysOne tablet daily with food for five daysOral route1901-03-02 to 1901-03-06completedS
Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeksOne tablet twice daily for two weeksOral route1901-03-02 to 1901-03-16completedS
Naltrexone 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1901-03-09 to 1901-03-30completedS
Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse380 mg intramuscularly every four weeksIntramuscular route1901-03-30activeS
Amoxicillin 500 mg oral capsule, one capsule three times daily for five daysOne capsule three times daily for five daysOral route1901-03-23 to 1901-03-28completedS
Ibuprofen 400 mg oral tablet, one tablet with food every 8 hours as needed for tooth pain, for up to five daysOne tablet with food every 8 hours as needed, up to five daysOral route1901-03-23 to 1901-03-28completedS
Acetaminophen 500 mg oral tablet, one tablet every 6 hours as needed with the ibuprofen, no more than 2,000 mg a day, for up to five daysOne tablet every 6 hours as needed, no more than 2,000 mg a dayOral route1901-03-23 to 1901-03-28completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1901-05-11Body height165cmS
1901-05-11Body weight51.8kgS
1901-05-11Body mass index (BMI) [Ratio]19kg/m2S
1901-05-11Systolic blood pressure118mm[Hg]S
1901-05-11Diastolic blood pressure76mm[Hg]S
1901-05-11Heart rate74/minS
1901-05-11Respiratory rate16/minS
1901-05-11Body temperature36.6CelS
1901-05-11Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1901-05-11Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1901-05-11Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 1901-05-11; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/76, pulse 74; weight 51.8 kg, BMI 19.0
SkinButtock injection sites without induration
PsychiatricBright, joking, engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis.
Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checksresolvedconfirmed F10.230S — Synthetic withdrawal episode; resolved by the one-week visit.
Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement plannedresolvedconfirmed R74.01S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease.
Alcohol-associated steatotic liver disease, without cirrhosis: liver stiffness 9.6 kPa after four weeks without alcohol, falling enzymes, normal bilirubin, albumin, INR and plateletsactiveconfirmed K70.0S — Synthetic modern diagnosis made at the four-week visit.
Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcoholresolvedprovisional F32.AS — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood.
Daily chewing tobacco for many years; not ready to stop at intakeactiveconfirmed F17.220S — Synthetic modern coding anchored to the documented chewing tobacco.
Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albuminactiveconfirmed R63.6S — Synthetic finding anchored to a contemporary impression of poor nutrition (R).
Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past wintersactiveconfirmed Z59.811S — Synthetic social need anchored to her documented poverty and moves from town to town.
Food insecurity: often goes without meals at the end of the monthactiveconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.
Periapical abscess of a lower left molar with facial swelling and low-grade fever, on naltrexone; treated without opioids, tooth removed at the dental clinic the next day; resolvedresolvedconfirmed K04.7S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementDrinking since the last visit (her own account, day by day), cravings and triggersEvery visitCompleted todayNo alcohol for ten weeks
LaboratoryPEth, explained as part of care and not as a test of honestyAt baseline and about every one to two monthsUp to date24 ng/mL at four weeks; next at sixteen weeks
Medication safetyMedicine for alcohol use disorder: adherence, side effects, opioid exposureEvery visitCompleted todayExtended-release naltrexone at four weeks and eight weeks; no injection-site reaction
LaboratoryLiver enzymes on naltrexoneBaseline, within the first months of treatment, then periodicallyUp to dateFalling at four weeks; recheck at sixteen weeks
ImagingLiver fibrosis: FIB-4, transient elastography, albumin, INR, plateletsElastography when FIB-4 is above 2.67, repeated after months without alcoholUp to date9.6 kPa at four weeks; repeat at sixteen weeks
ExaminationWeight, meals and food accessEvery visitCompleted todayWeight 51.8 kg, BMI 19.0; SNAP and the food bank
SurveyDepression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcoholAt baseline, after two to four weeks without alcohol, then at least monthly while symptoms persistCompleted todayPHQ-9 5, item 9 scored 0; GAD-7 5
SurveySuicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; rifle still with her friend; 988 saved in her new phone
Self-managementPeer recovery support and mutual-help meetingsWeekly peer contact; meetings of her choiceDeferredNo peer contact for about two weeks in early April, when she had no phone. No harm resulted: she did not drink, and she went to her Thursday meeting. Corrective action: a free Lifeline phone was arranged, and the peer specialist now confirms each week's call by text
Self-managementHousing, food, income and health coverageEvery visitCompleted todayA rented room of her own through the housing program; Medicaid and SNAP active
Self-managementChewing tobaccoEvery visitCompleted todayStill chewing; nicotine lozenges offered again
Medication safetyNaloxoneReassess at every visitNot indicatedNo opioid use

Goal progress:

Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Naltrexone injection at a nurse visit in two weeks. Sixteen-week review in six weeks with blood tests, PEth and elastography. Mammogram next month. Next scheduled visit 1901-06-22: sixteen-week review after a two-day return to drinking: liver tests, PEth, elastography and the plan ahead. [S]